ClinicalTrials.gg
CompletedNCT01200368Updated Dec 19, 2018Results posted

Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine (13vPnC) and diphtheria, tetanus, and acellular pertussis vaccine (DTaP) in Healthy Subjects, sponsored by Pfizer. Completed at 32 sites in Japan. Open to participants aged 3 Months to 6 Months. Per ClinicalTrials.gov, last updated 2018-12-19.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
551
Allocation
Randomized
Ages
3 Months to 6 Months
Sex
All
01

Study summary

Subjects will be randomly assigned to 1 of 3 groups to receive the following vaccines: Group 1: 13-valent pneumococcal conjugate vaccine (13vPnC) and diphtheria, tetanus, and acellular pertussis vaccine (DTaP), Group 2: 7-valent pneumococcal conjugate vaccine (7vPnC) and DTaP, Group 3: DTaP alone. Group 3 subjects will also receive catch-up doses of Prevenar (commercial product of Prevenar in Japan) 13vPnC and 7vPnC will be blinded, and DTaP will be open-label. The main purpose of the study is to determine if the immune responses to 13vPnC are comparable to the immune responses to 7vPnC and if the immune responses to 13vPnC given with DTaP are comparable to those induced by DTaP given alone. In addition, the study aims to evaluate the side effects (safety profile) after vaccination of 13vPnC and 7vPnC when given with DTaP in healthy Japanese infants.

02

Conditions studied

  • Healthy Subjects

Keywords

  • vaccine
  • pneumococcal conjugate
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 3 to 6 months of age at the enrollment.
  • Available for the entire study period and whose parent/legal guardian can be reached by telephone.
  • Healthy infant as determined by medical history, physical examination, and judgement of the investigator.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with licensed or pneumococcal, diphtheria, tetanus, or pertussis vaccines.
  • A previous anaphylactic reaction to any vaccine or vaccine-related component.
  • Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
  • History of culture-proven invasive disease caused by S pneumoniae (eg, meningitis, bacteremia, osteomyelitis, arthritis).
  • Infant who is a direct descendant (child, grandchild) of the study site personnel.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
551 participants (actual)

Study arms

  • Experimental
    1

    Experimental

    Biological: 13-valent pneumococcal conjugate vaccine (13vPnC) · Biological: diphtheria, tetanus, and acellular pertussis vaccine (DTaP)

  • Active comparator
    2

    Active comparator

    Biological: 7-valent pneumococcal conjugate vaccine (7vPnC) · Biological: DTaP

  • Active comparator
    3

    Active comparator

    Biological: DTaP

Interventions

  • 0.5 mL per dose, 4 doses

  • Biologicaldiphtheria, tetanus, and acellular pertussis vaccine (DTaP)

    0.5 mL per dose, 4 doses

  • Biological7-valent pneumococcal conjugate vaccine (7vPnC)

    0.5 mL per dose, 4 doses

  • BiologicalDTaP

    0.5 mL per dose, 4 doses

  • BiologicalDTaP

    0.5 mL per dose, 4 doses

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series

    Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.

    Time frame: 1 month after the infant series

  2. Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 7 Common Serotypes 1 Month After the Infant Series

    Antibody geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.

    Time frame: 1 month after the infant series

  3. Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Infant Series

    Predefined antibody levels were 0.1 International Units/mL (IU/mL) for diphtheria, 0.01 IU/mL for tetanus, 5 Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) for pertussis toxoid (PT), and 5 EU/mL for filamentous hemagglutinin (FHA).

    Time frame: 1 month after the infant series

Secondary outcomes

  1. Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 6 Additional Serotypes 1 Month After the Infant Series

    Antibody GMC for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMs were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.

    Time frame: 1 month after the infant series

  2. Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level >=0.35 mcg/mL 1 Month After the Toddler Dose

    Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.

    Time frame: 1 month after the toddler dose

  3. Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose

    Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.

    Time frame: 1 month after the toddler dose

  4. Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Toddler Dose

    Predefined antibody level was 0.1 IU/mL for diphtheria, 0.01 IU/mL for tetanus, 5 EU/mL for PT, and 5 EU/mL for FHA.

    Time frame: 1 month after the toddler dose

  5. Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibodies 1 Month After the Infant Series

    GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.

    Time frame: 1 month after the infant series

  6. Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibodies 1 Month After the Infant Series

    GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.

    Time frame: 1 month after the infant series

  7. Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibody 1 Month After the Toddler Dose

    GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.

    Time frame: 1 month after the toddler dose

  8. Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibody 1 Month After the Toddler Dose

    GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.

    Time frame: 1 month after the toddler dose

Other outcomes

  1. Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 1 (3 to 6 Months of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after Dose 1 of the infant series

  2. Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 2 (4 to 8 Months of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after Dose 2 of the infant series

  3. Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 3 (5 to 10 Months of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after Dose 3 of the infant series

  4. Percentage of Participants Reporting Pre-Specified Local Reactions: Toddler Dose (12 to 15 Months of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after the toddler dose

  5. Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (3 to 6 Months of Age)

    Systemic events (any fever \>= 37.5 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after Dose 1 of infant series

  6. Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 to 8 Months of Age)

    Systemic events (any fever \>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after Dose 2 of infant series

  7. Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (5 to 10 Months of Age)

    Systemic events (any fever \>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after Dose 3 of infant series

  8. Percentage of Participants Reporting Pre-Specified Systemic Events: Toddler Dose (12 to 15 Months of Age)

    Systemic events (any fever \>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after the toddler dose

07

Results

Posted Oct 12, 2012

Participant flow

Infant Series
Participant flow — Infant Series
Milestone13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Started183184184
Vaccinated dose 1183183183
Vaccinated dose 2183182183
Vaccinated dose 3181178182
Completed180178178
Not completed366
Withdrew: Adverse event223
Withdrew: Withdrawal by subject022
Withdrew: Did not meet entrance criteria010
Withdrew: Randomized, not vaccinated011
Withdrew: Other100
After Infant Series
Participant flow — After Infant Series
Milestone13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Started180178178
Completed162162169
Not completed18169
Withdrew: Adverse event663
Withdrew: Withdrawal by subject1084
Withdrew: Lost to follow-up100
Withdrew: Other122
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Started162162169
Completed162159168
Not completed031
Withdrew: Adverse event031

Outcome measures

PrimaryPercentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series

Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.

Time frame:
1 month after the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series
percentage of participants13vPnC + DTaP7vPnC + DTaP
4100.0 (97.9 to 100.0)100.0 (97.9 to 100.0)
6B97.7 (94.3 to 99.4)99.4 (96.9 to 100.0)
9V100.0 (97.9 to 100.0)100.0 (97.9 to 100.0)
14100.0 (97.9 to 100.0)100.0 (97.9 to 100.0)
18C100.0 (97.9 to 100.0)100.0 (97.9 to 100.0)
19F98.9 (96.0 to 99.9)96.6 (92.7 to 98.7)
23F97.7 (94.3 to 99.4)98.3 (95.1 to 99.6)
1100.0 (97.9 to 100.0)96.6 (92.7 to 98.7)
399.4 (96.9 to 100.0)96.6 (92.7 to 98.7)
599.4 (96.9 to 100.0)96.6 (92.7 to 98.7)
6A98.3 (95.1 to 99.6)96.6 (92.7 to 98.7)
7F100.0 (97.9 to 100.0)96.6 (92.7 to 98.7)
19A100.0 (97.9 to 100.0)96.6 (92.7 to 98.7)
Statistical analysis
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.0 · 95% CI -2.2 to 2.1
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: -1.7 · 95% CI -5.2 to 1.1
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.0 · 95% CI -2.1 to 2.1
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.0 · 95% CI -2.1 to 2.1
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.0 · 95% CI -2.1 to 2.1
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 2.3 · 95% CI -1.1 to 6.3
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: -0.6 · 95% CI -4.2 to 2.9
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 3.4 · 95% CI 0.9 to 7.3
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 2.9 · 95% CI -0.2 to 6.7
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 2.9 · 95% CI -0.2 to 6.7
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 1.7 · 95% CI -1.9 to 5.8
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 3.4 · 95% CI 0.9 to 7.3
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 3.4 · 95% CI 1.0 to 7.3
PrimaryGeometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 7 Common Serotypes 1 Month After the Infant Series

Antibody geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.

Time frame:
1 month after the infant series
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 7 Common Serotypes 1 Month After the Infant Series
mcg/mL13vPnC + DTaP7vPnC + DTaP
49.40 (8.48 to 10.41)11.54 (10.51 to 12.67)
6B4.50 (3.90 to 5.21)5.71 (4.93 to 6.63)
9V5.04 (4.52 to 5.62)6.80 (6.15 to 7.52)
1413.86 (12.16 to 15.80)16.79 (15.03 to 18.76)
18C5.30 (4.75 to 5.91)7.26 (6.53 to 8.08)
19F7.37 (6.43 to 8.46)8.38 (7.17 to 9.80)
23F3.64 (3.16 to 4.19)4.53 (3.96 to 5.18)
Statistical analysis
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 0.81 · 95% CI 0.71 to 0.94
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 0.79 · 95% CI 0.64 to 0.97
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 0.74 · 95% CI 0.64 to 0.86
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 0.83 · 95% CI 0.70 to 0.98
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 0.73 · 95% CI 0.63 to 0.85
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 0.88 · 95% CI 0.72 to 1.08
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 0.80 · 95% CI 0.66 to 0.98
PrimaryPercentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Infant Series

Predefined antibody levels were 0.1 International Units/mL (IU/mL) for diphtheria, 0.01 IU/mL for tetanus, 5 Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) for pertussis toxoid (PT), and 5 EU/mL for filamentous hemagglutinin (FHA).

Time frame:
1 month after the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Infant Series
percentage of participants13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Diphtheria99.4 (96.9 to 100.0)96.6 (92.7 to 98.7)100.0 (97.9 to 100.0)
Tetanus100.0 (97.9 to 100.0)100.0 (97.9 to 100.0)100.0 (97.9 to 100.0)
Pertussis toxoid (PT)99.4 (96.9 to 100.0)96.6 (92.7 to 98.7)100.0 (97.9 to 100.0)
Filamentous hemagglutinin (FHA)99.4 (96.9 to 100.0)96.6 (92.7 to 98.7)100.0 (97.9 to 100.0)
Statistical analysis
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Percent difference: -0.6 · 95% CI -3.1 to 1.6
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Percent difference: 0.0 · 95% CI -2.1 to 2.2
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Percent difference: -0.6 · 95% CI -3.1 to 1.6
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Percent difference: -0.6 · 95% CI -3.1 to 1.6
SecondaryGeometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 6 Additional Serotypes 1 Month After the Infant Series

Antibody GMC for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMs were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.

Time frame:
1 month after the infant series
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 6 Additional Serotypes 1 Month After the Infant Series
mcg/mL13vPnC + DTaP7vPnC + DTaP
18.14 (7.23 to 9.18)4.53 (3.96 to 5.18)
34.90 (4.43 to 5.42)4.53 (3.96 to 5.18)
54.64 (4.14 to 5.20)4.53 (3.96 to 5.18)
6A4.71 (4.15 to 5.34)4.53 (3.96 to 5.18)
7F8.26 (7.45 to 9.17)4.53 (3.96 to 5.18)
19A8.56 (7.67 to 9.56)4.53 (3.96 to 5.18)
Statistical analysis
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 1.80 · 95% CI 1.50 to 2.15
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 1.08 · 95% CI 0.92 to 1.28
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 1.03 · 95% CI 0.86 to 1.22
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 1.04 · 95% CI 0.87 to 1.25
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 1.83 · 95% CI 1.54 to 2.16
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 1.89 · 95% CI 1.59 to 2.25
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level >=0.35 mcg/mL 1 Month After the Toddler Dose

Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.

Time frame:
1 month after the toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level >=0.35 mcg/mL 1 Month After the Toddler Dose
percentage of participants13vPnC + DTaP7vPnC + DTaP
4100.0 (97.7 to 100.0)100.0 (97.6 to 100.0)
6B100.0 (97.7 to 100.0)100.0 (97.6 to 100.0)
9V100.0 (97.7 to 100.0)100.0 (97.6 to 100.0)
14100.0 (97.7 to 100.0)100.0 (97.6 to 100.0)
18C100.0 (97.7 to 100.0)100.0 (97.6 to 100.0)
19F98.7 (95.5 to 99.8)99.4 (96.4 to 100.0)
23F100.0 (97.7 to 100.0)100.0 (97.6 to 100.0)
199.4 (96.5 to 100.0)99.4 (96.4 to 100.0)
399.4 (96.5 to 100.0)99.4 (96.4 to 100.0)
5100.0 (97.7 to 100.0)99.4 (96.4 to 100.0)
6A100.0 (97.7 to 100.0)99.4 (96.4 to 100.0)
7F100.0 (97.7 to 100.0)99.4 (96.4 to 100.0)
19A100.0 (97.7 to 100.0)99.4 (96.4 to 100.0)
Statistical analysis
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.0 · 95% CI -2.4 to 2.4
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.0 · 95% CI -2.4 to 2.4
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.0 · 95% CI -2.4 to 2.4
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.0 · 95% CI -2.4 to 2.4
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.0 · 95% CI -2.4 to 2.4
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: -0.6 · 95% CI -3.9 to 2.4
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.0 · 95% CI -2.4 to 2.4
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.0 · 95% CI -2.9 to 3.0
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.0 · 95% CI -2.9 to 3.0
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.6 · 95% CI -1.7 to 3.6
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.6 · 95% CI -1.7 to 3.6
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.6 · 95% CI -1.7 to 3.6
  • 13vPnC + DTaP vs 7vPnC + DTaP · Percent difference: 0.6 · 95% CI -1.7 to 3.6
SecondaryGeometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose

Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.

Time frame:
1 month after the toddler dose
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose
mcg/mL13vPnC + DTaP7vPnC + DTaP
415.34 (13.23 to 17.79)16.35 (14.19 to 18.83)
6B17.05 (14.47 to 20.08)13.91 (11.93 to 16.21)
9V7.00 (6.11 to 8.03)8.64 (7.54 to 9.89)
1419.70 (17.69 to 21.93)20.69 (18.25 to 23.47)
18C8.10 (6.94 to 9.47)9.88 (8.64 to 11.30)
19F16.73 (14.20 to 19.71)9.55 (8.11 to 11.26)
23F8.64 (7.46 to 10.01)10.00 (8.61 to 11.62)
113.96 (11.94 to 16.31)8.64 (7.54 to 9.89)
32.48 (2.17 to 2.85)8.64 (7.54 to 9.89)
511.10 (9.83 to 12.53)8.64 (7.54 to 9.89)
6A15.17 (13.31 to 17.30)8.64 (7.54 to 9.89)
7F10.90 (9.54 to 12.45)8.64 (7.54 to 9.89)
19A16.02 (14.07 to 18.25)8.64 (7.54 to 9.89)
Statistical analysis
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 0.94 · 95% CI 0.77 to 1.15
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 1.23 · 95% CI 0.98 to 1.53
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 0.81 · 95% CI 0.67 to 0.98
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 0.95 · 95% CI 0.81 to 1.12
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 0.82 · 95% CI 0.67 to 1.01
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 1.75 · 95% CI 1.39 to 2.21
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 0.86 · 95% CI 0.70 to 1.07
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 1.62 · 95% CI 1.31 to 1.99
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 0.29 · 95% CI 0.24 to 0.35
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 1.28 · 95% CI 1.07 to 1.54
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 1.76 · 95% CI 1.46 to 2.12
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 1.26 · 95% CI 1.04 to 1.52
  • 13vPnC + DTaP vs 7vPnC + DTaP · Gmc ratio: 1.85 · 95% CI 1.54 to 2.24
SecondaryPercentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Toddler Dose

Predefined antibody level was 0.1 IU/mL for diphtheria, 0.01 IU/mL for tetanus, 5 EU/mL for PT, and 5 EU/mL for FHA.

Time frame:
1 month after the toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Toddler Dose
percentage of participants13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Diphtheria100.0 (97.7 to 100.0)100.0 (97.6 to 100.0)100.0 (97.8 to 100.0)
Tetanus100.0 (97.7 to 100.0)100.0 (97.6 to 100.0)100.0 (97.8 to 100.0)
Pertussis toxoid (PT)100.0 (97.7 to 100.0)100.0 (97.6 to 100.0)100.0 (97.8 to 100.0)
Filamentous hemagglutinin (FHA)100.0 (97.7 to 100.0)100.0 (97.6 to 100.0)100.0 (97.8 to 100.0)
Statistical analysis
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Percent difference: 0.0 · 95% CI -2.4 to 2.3
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Percent difference: 0.0 · 95% CI -2.4 to 2.3
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Percent difference: 0.0 · 95% CI -2.4 to 2.3
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Percent difference: 0.0 · 95% CI -2.4 to 2.3
SecondaryGeometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibodies 1 Month After the Infant Series

GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.

Time frame:
1 month after the infant series
Reported as:
Geometric mean · IU/mL
Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibodies 1 Month After the Infant Series
IU/mL13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Diphtheria1.03 (0.94 to 1.12)1.10 (0.97 to 1.25)0.93 (0.86 to 1.02)
Tetanus1.50 (1.31 to 1.70)1.37 (1.17 to 1.60)1.66 (1.50 to 1.83)
Statistical analysis
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Gmc ratio: 1.10 · 95% CI 0.97 to 1.24
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Gmc ratio: 0.90 · 95% CI 0.77 to 1.06
SecondaryGeometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibodies 1 Month After the Infant Series

GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.

Time frame:
1 month after the infant series
Reported as:
Geometric mean · EU/mL
Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibodies 1 Month After the Infant Series
EU/mL13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Pertussis toxoid (PT)66.12 (60.45 to 72.32)57.26 (49.23 to 66.60)67.64 (62.87 to 72.78)
Filamentous hemagglutinin (FHA)62.30 (56.59 to 68.59)53.86 (47.27 to 61.37)67.48 (61.64 to 73.86)
Statistical analysis
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Gmc ratio: 0.98 · 95% CI 0.87 to 1.10
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Gmc ratio: 0.92 · 95% CI 0.81 to 1.05
SecondaryGeometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibody 1 Month After the Toddler Dose

GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.

Time frame:
1 month after the toddler dose
Reported as:
Geometric mean · IU/mL
Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibody 1 Month After the Toddler Dose
IU/mL13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Diphtheria2.65 (2.43 to 2.90)3.18 (2.94 to 3.45)2.63 (2.39 to 2.91)
Tetanus2.90 (2.56 to 3.28)2.60 (2.29 to 2.95)2.89 (2.58 to 3.25)
Statistical analysis
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Gmc ratio: 1.01 · 95% CI 0.88 to 1.15
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Gmc ratio: 1.00 · 95% CI 0.85 to 1.19
SecondaryGeometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibody 1 Month After the Toddler Dose

GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.

Time frame:
1 month after the toddler dose
Reported as:
Geometric mean · EU/mL
Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibody 1 Month After the Toddler Dose
EU/mL13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Pertussis toxoid (PT)144.46 (130.68 to 159.68)135.65 (124.16 to 148.21)150.21 (136.20 to 165.65)
Filamentous hemagglutinin (FHA)143.68 (130.94 to 157.66)141.19 (129.20 to 154.30)180.31 (163.12 to 199.32)
Statistical analysis
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Gmc ratio: 0.96 · 95% CI 0.84 to 1.11
  • 13vPnC + DTaP vs DTaP (Catch-up 7vPnC) · Gmc ratio: 0.80 · 95% CI 0.70 to 0.91
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 1 (3 to 6 Months of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after Dose 1 of the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 1 (3 to 6 Months of Age)
percentage of participants13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Redness- Any (n=171, 172, 165)58.555.810.3
Redness- Mild (n=170, 172, 165)48.251.210.3
Redness- Moderate (n=164, 166, 162)18.918.10.0
Redness- Severe (n=161, 162, 162)0.00.60.0
Swelling- Any (n=168, 168, 164)41.135.74.9
Swelling- Mild (n= 168, 168, 164)38.131.54.9
Swelling- Moderate (n=162, 165, 162)12.312.70.0
Swelling- severe (n=161, 162, 162)0.00.60.0
Tenderness- Any (n=163, 164, 162)13.56.11.2
Tenderness- Significant (n=161, 162, 162)0.00.00.0
Any local reaction (n=175, 174, 165)68.060.912.1
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 2 (4 to 8 Months of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after Dose 2 of the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 2 (4 to 8 Months of Age)
percentage of participants13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Redness- Any (n= 166, 168, 161)62.761.936.6
Redness- Mild (n= 166, 167, 161)56.056.934.8
Redness- Moderate (n= 157, 159, 156)26.127.08.3
Redness- Severe (n= 157, 154, 154)0.00.00.0
Swelling- Any (n= 160, 171, 162)48.150.924.1
Swelling- Mild (n= 160, 170, 162)44.448.222.8
Swelling- Moderate (n= 157, 157, 155)19.717.85.8
Swelling- severe (n= 157, 154, 154)0.00.00.0
Tenderness- Any (n= 159, 154, 155)14.54.51.9
Tenderness- Significant (n= 157, 154, 154)0.60.00.0
Any local reaction (n=167, 173, 164)71.367.140.2
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 3 (5 to 10 Months of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after Dose 3 of the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 3 (5 to 10 Months of Age)
percentage of participants13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Redness- Any (n= 168, 162, 156)53.651.223.1
Redness- Mild (n= 167, 160, 156)47.343.121.8
Redness- Moderate (n= 152, 154, 153)17.122.12.0
Redness- Severe (n= 149, 152, 152)0.00.00.0
Swelling- Any (n= 164, 157, 159)43.937.621.4
Swelling- Mild (n= 164, 156, 159)42.134.020.1
Swelling- Moderate (n= 150, 154, 153)10.714.92.6
Swelling- severe (n= 149, 152, 152)0.00.00.0
Tenderness- Any (n= 153, 155, 153)7.87.12.6
Tenderness- Significant (n= 149, 152, 152)0.00.00.7
Any local reaction (n=171, 163, 160)62.055.828.8
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Local Reactions: Toddler Dose (12 to 15 Months of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after the toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions: Toddler Dose (12 to 15 Months of Age)
percentage of participants13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Redness- Any (n= 148, 152, 149)62.257.234.9
Redness- Mild (n= 148, 151, 148)50.047.728.4
Redness- Moderate (n= 141, 139, 145)27.727.313.1
Redness- Severe (n= 140, 136, 141)0.00.00.0
Swelling- Any (n= 149, 144, 148)49.045.826.4
Swelling- Mild (n= 147, 143, 146)42.942.022.6
Swelling- Moderate (n= 143, 138, 146)16.818.813.0
Swelling- severe (n= 140, 136, 141)0.00.00.0
Tenderness- Any (n= 142, 140 ,142)14.110.05.6
Tenderness- Significant (n= 140, 136, 141)0.70.00.0
Any local reaction (n=153, 152, 151)68.661.837.1
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (3 to 6 Months of Age)

Systemic events (any fever \>= 37.5 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after Dose 1 of infant series
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (3 to 6 Months of Age)
percentage of participants13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Fever >=37.5,=<39 degrees C (n=168, 168, 165)36.333.921.8
Fever >39,=<40 degrees C (n=161, 163, 162)0.61.20.6
Fever >40 degrees C (n=161, 162, 162)0.00.00.0
Decreased appetite (n=163, 163, 165)12.99.27.3
Irritability (n=165, 164, 164)18.816.512.2
Increased sleep (n=170, 165, 165)28.826.721.8
Decreased sleep (n=164, 169, 167)18.321.313.8
Hives- urticaria (n=161, 162, 162)3.11.20.0
Use of antipyretic medication (n= 161, 162, 162)3.72.50.6
Any systemic event (n=177, 174, 172)61.059.843.0
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 to 8 Months of Age)

Systemic events (any fever \>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after Dose 2 of infant series
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 to 8 Months of Age)
percentage of participants13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Fever >=37.5, =<39 degrees C (n=166, 161, 155)36.736.621.9
Fever >39, =<40 degrees C (n=158, 155, 154)1.93.90.6
Fever >40 degrees C (n=157, 154, 154)0.00.00.0
Decreased appetite (n=158, 159, 155)11.414.57.1
Irritability (n=162, 155, 156)17.918.710.9
Increased sleep (n=163, 158, 163)22.722.222.7
Decreased sleep (n=161, 157, 157)18.612.112.1
Hives- urticaria (n=157, 154, 154)2.51.31.9
Use of antipyretic medication (n=160, 155, 154)3.14.51.3
Any systemic event (n=170, 169, 166)61.257.444.6
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (5 to 10 Months of Age)

Systemic events (any fever \>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after Dose 3 of infant series
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (5 to 10 Months of Age)
percentage of participants13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Fever >=37.5, =<39 degrees C (n=162, 161, 157)34.630.424.2
Fever >39, =<40 degrees C (n=150, 152, 153)3.32.03.3
Fever >40 degrees C (n=149, 152, 152)0.00.70.0
Decreased appetite (n=152, 155, 154)9.99.75.8
Irritability (n=154, 156, 154)17.514.711.7
Increased sleep (n=151, 157, 154)20.520.414.9
Decreased sleep (n= 154, 156, 153)18.212.89.8
Hives- urticaria (n= 149, 152, 152)1.30.01.3
Use of antipyretic medication (n=150, 153, 154)2.03.34.5
Any systemic event (n=168, 164, 159)57.750.040.9
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events: Toddler Dose (12 to 15 Months of Age)

Systemic events (any fever \>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after the toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events: Toddler Dose (12 to 15 Months of Age)
percentage of participants13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)
Fever >=37.5, =<39 degrees C (n=145, 146, 146)49.049.331.5
Fever >39, =<40 degrees C (n=141, 136, 141)4.38.83.5
Fever >40 degrees C (n=139, 137, 141)1.42.20.0
Decreased appetite (n=143, 141, 143)19.619.99.8
Irritability (n=143, 141, 144)18.221.316.7
Increased sleep (n=145, 142, 143)18.617.616.1
Decreased sleep (n=142, 137, 141)12.79.511.3
Hives- urticaria (n=140, 136, 141)3.62.22.1
Use of antipyretic medication (n=141, 138, 142)7.19.44.2
Any systemic event (n=148, 152, 149)62.863.850.3

Adverse events

Collected over AEs/SAEs: recorded from signing of informed consent form to completion of study. Participants recorded pre-specified AEs in electronic diary:local reactions; systemic events; use of antipyretic medication (up to 7 days after each vaccine dose).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC + DTaP - Infant Series—5/183 (2.7%)147/183 (80.3%)
7vPnC + DTaP - Infant Series—8/183 (4.4%)160/183 (87.4%)
DTaP (Catch-up 7vPnC) - Infant Series—10/183 (5.5%)155/183 (84.7%)
13vPnC + DTaP - After the Infant Series—13/183 (7.1%)20/183 (10.9%)
7vPnC + DTaP - After the Infant Series—15/183 (8.2%)27/183 (14.8%)
DTaP (Catch-up 7vPnC) - After the Infant Series—10/183 (5.5%)147/183 (80.3%)
13vPnC + DTaP - Toddler Dose—0/162 (0%)104/162 (64.2%)
7vPnC + DTaP - Toddler Dose—4/162 (2.5%)99/162 (61.1%)
DTaP (Catch-up 7vPnC) - Toddler Dose—2/169 (1.2%)112/169 (66.3%)
DTaP (Catch-up 7vPnC) - After the Toddler Dose—2/169 (1.2%)105/169 (62.1%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
Event13vPnC + DTaP - Infant Series7vPnC + DTaP - Infant SeriesDTaP (Catch-up 7vPnC) - Infant Series13vPnC + DTaP - After the Infant Series7vPnC + DTaP - After the Infant SeriesDTaP (Catch-up 7vPnC) - After the Infant Series13vPnC + DTaP - Toddler Dose7vPnC + DTaP - Toddler DoseDTaP (Catch-up 7vPnC) - Toddler DoseDTaP (Catch-up 7vPnC) - After the Toddler Dose
Febrile convulsionNervous system disorders0/1831/1831/1836/1835/1833/1830/1623/1621/1692/169
GastroenteritisInfections and infestations1/1831/1830/1830/1833/1830/1830/1620/1620/1690/169
PneumoniaInfections and infestations1/1830/1830/1830/1830/1833/1830/1621/1620/1690/169
Respiratory syncytial virus bronchiolitisInfections and infestations1/1830/1833/1831/1830/1830/1830/1620/1620/1690/169
BronchitisInfections and infestations1/1831/1830/1831/1832/1830/1830/1620/1620/1690/169
Pneumonia respiratory syncytial viralInfections and infestations0/1830/1832/1830/1830/1830/1830/1620/1620/1690/169
Kawasaki's diseaseVascular disorders0/1830/1832/1831/1831/1830/1830/1620/1620/1690/169
Gastroenteritis rotavirusInfections and infestations0/1830/1830/1830/1832/1831/1830/1620/1620/1690/169
AsthmaRespiratory, thoracic and mediastinal disorders0/1830/1830/1831/1830/1831/1830/1621/1620/1690/169
Respiratory syncytial virus infectionInfections and infestations0/1830/1830/1830/1830/1830/1830/1620/1621/1690/169
Most frequent other events
Showing 10 of 215
Most frequent other events
Event13vPnC + DTaP - Infant Series7vPnC + DTaP - Infant SeriesDTaP (Catch-up 7vPnC) - Infant Series13vPnC + DTaP - After the Infant Series7vPnC + DTaP - After the Infant SeriesDTaP (Catch-up 7vPnC) - After the Infant Series13vPnC + DTaP - Toddler Dose7vPnC + DTaP - Toddler DoseDTaP (Catch-up 7vPnC) - Toddler DoseDTaP (Catch-up 7vPnC) - After the Toddler Dose
Redness (Any)Skin and subcutaneous tissue disorders104/166104/16859/161———————
Redness (Any)Skin and subcutaneous tissue disorders100/17196/17217/165———92/14887/15252/149—
Redness (Mild)Skin and subcutaneous tissue disorders93/16695/16756/161———————
Redness (Any)Skin and subcutaneous tissue disorders90/16883/16236/156———————
Redness (Mild)Skin and subcutaneous tissue disorders82/17088/17217/165———74/14872/15142/148—
Swelling (Any)Skin and subcutaneous tissue disorders77/16087/17139/162———————
Fever >=37.5, =<39 degrees CGeneral disorders61/16857/16836/165———71/14572/14646/146—
Swelling (Any)Skin and subcutaneous tissue disorders69/16860/1688/164———73/14966/14439/148—
Swelling (Mild)Skin and subcutaneous tissue disorders71/16082/17037/162———————
Redness (Mild)Skin and subcutaneous tissue disorders79/16769/16034/156———————

Baseline characteristics

Age, Continuous
Age, Continuous(months)13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)Total
Mean4.1 ± 0.974.1 ± 0.974.2 ± 0.964.1 ± 0.97
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC + DTaP7vPnC + DTaPDTaP (Catch-up 7vPnC)Total
Female879191269
Male969393282
08

Study locations

32 sites
  • Sunrise Children's Clinic
    Funabashi, Chiba 273-0035, Japan
  • Sotobo Children's Clinic
    Isumi-city, Chiba 299-4503, Japan
  • Matsuyama Red Cross Hospital
    Matsuyama-city, Ehime 790-8524, Japan
  • Fukazawa Pediatric Clinic
    Higashi-ku, Fukuoka-city, Fukuoka 813-0036, Japan
  • National Hospital Organization Fukuyama Medical Center
    Fukuyama, Hiroshima 720-8520, Japan
  • National Hospital Organization Kure Medical Center
    Kure, Hiroshima 737-0023, Japan
  • Nakata pediatric clinic
    Sapporo, Hokkaido 003-0023, Japan
  • Watanabe Pediatric Allergy Clinic
    Sapporo, Hokkaido 006-0831, Japan
  • Furuta Children's Clinic
    Sapporo, Hokkaido 063-0831, Japan
  • Motomachi pediatric clinic
    Sapporo, Hokkaido 065-0024, Japan
  • Tenshi Hospital
    Sapporo, Hokkaido 065-8611, Japan
  • Yoshimoto Pediatrist Clinic
    Kikuchi-gun, Kumamoto 869-1102, Japan
  • Shiroko Clinic
    Suzuka, MIE 510-0235, Japan
  • National Mie Hospital
    Tsu, MIE 514-0125, Japan
  • National hospital Organization Mie Chuou Medical Center
    Tsu, MIE 514-1101, Japan
  • Shibuya Clinic
    Kumagaya-city, Saitama 360-0812, Japan
  • Children's Enomoto Clinic
    Kumagaya, Saitama 360-0018, Japan
  • Sakiyama Children's Clinic
    Fuchu, Tokyo 183-0042, Japan
  • Okawa Children and Family Clinic
    Ota-ku, Tokyo 146-0095, Japan
  • Seijo Sasamoto Pediatric And Allergy Clinic
    Setagaya-ku, Tokyo 157-0066, Japan
  • National Center for Child Health and Development
    Setagaya-ku, Tokyo 157-8535, Japan
  • Miyata Pediatric Clinic
    Tachikawa-shi, Tokyo 190-0002, Japan
  • Maehara Pediatric Clinic
    Tama, Tokyo 206-0011, Japan
  • Childrens Clinic of Kose
    Kofu, Yamanashi 400-0853, Japan
  • Medical Corporation Bunpoukai Amemiya Clinic
    Koushu-shi, Yamanashi 404-0046, Japan
  • Medical Corporation Seijinkai Takei Clinic
    Tsuru-shi, Yamanashi 402-0025, Japan
  • National Hospital Organization Fukuoka National Hospital
    Fukuoka, 811-1394, Japan
  • Harada Clinic
    Fukuoka, 816-0094, Japan
  • Hattori Pediatric Clinic
    Kumamoto, 860-0812, Japan
  • Medical Corporation Seiaikai Seguchi Pediatric Clinic
    Kumamoto, 860-0834, Japan
  • Medical Corporation Oukakai Sakuranbo Kodomo Clinic
    Kumamoto, 862-0924, Japan
  • Momotaro Clinic
    Okayama, 701-0205, Japan
09

References and documents

Publications

  • Togashi T, Okada K, Yamaji M, Thompson A, Gurtman A, Cutler M, Aizawa M, Gruber WC, Scott DA. Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan. Pediatr Infect Dis J. 2015 Oct;34(10):1096-104. doi: 10.1097/INF.0000000000000819. PubMed 26121200 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2010 to primary completion in Nov 2011, 14 months.

Results were first posted in Oct 2012, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2010
First posted
Sep 13, 2010
StartActual
Sep 24, 2010
Primary completionActual
Nov 30, 2011
CompletionActual
Nov 30, 2011
Results first posted
Oct 12, 2012
Last update
Dec 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01200368
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 13, 2010
Start date
Sep 24, 2010
Primary completion
Nov 30, 2011
Completion
Nov 30, 2011
Results posted
Oct 12, 2012
Last update
Dec 19, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion